Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vactosertib - MedPacto

Drug Profile

Vactosertib - MedPacto

Alternative Names: EW-7197; NOV 1301; TEW-7197

Latest Information Update: 09 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ewha Womans University
  • Developer AstraZeneca; Case Comprehensive Cancer Center; MedPacto; Merck & Co; National OncoVenture; Samsung Medical Center; Yonsei University Health System
  • Class Aniline compounds; Antineoplastics; Fluorine compounds; Imidazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gastric cancer
  • Phase I/II Colorectal cancer; Fibroma; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer
  • Phase I Multiple myeloma; Solid tumours

Most Recent Events

  • 06 Feb 2020 Samsung Medical Center plans a phase Ib trial for Pancreatic cancer (Combination-therapy, Metastatic disease) in South Korea (PO) in March 2020 (NCT04258072)
  • 09 Jan 2020 Vactosertib is still in phase I trial for Solid tumours (MedPacto pipeline, August 2019)
  • 07 Dec 2019 Updated adverse events data from a phase I trial in Multiple myeloma presented at the 61st Annual Meeting and Exposition of the American Society of Haematology (ASH-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top